Role of anesthetics in treating status epilepticus
One more piece in the puzzle Status epilepticus (SE) is a medical emergency that can lead to serious sequelae if left untreated. Benzodiazepines have become established as the first treatment of choice. 1 Benzodiazepine-refractory SE is typically treated with a nonsedating IV antiepileptic drug (AED), most frequently fosphenytoin, valproic acid, or levetiracetam. When SE is refractory to the second-line AED, continuous IV anesthetic drugs are considered, and particularly recommended in generalized convulsive SE. The myriad systemic complications that can result from the various anesthetic drug choices have been well documented. 2 Hence, additional nonsedating IV AEDs are often considered before anesthesia, particularly for patients with nonconvulsive SE (NCSE) who are hemodynamically stable and have not required intubation. 3, 4 The rationale behind early escalation to anesthetic drugs (so-called "therapeutic coma") is to avoid development of neuronal injury from excitotoxicity 5 and benzodiazepine resistance associated with prolonged seizures. 6 This practice has been called into question following a series of studies documenting higher mortality with the use of anesthetic drugs. [7] [8] [9] This has led many to shift away from early anesthesia in favor of further trials of nonsedating IV AEDs. An aerial survey of the current landscape appears muddy, and studies are urgently needed to clarify the optimal level of treatment aggressiveness in SE.
In this issue of Neurology ® , Alvarez et al. 10 add important new layers to the topography of the landscape. Taking advantage of a prospective multicenter SE registry, the authors evaluated whether therapeutic coma affected mortality and duration of hospital stay, in 2 health systems, one in Switzerland and the other in Massachusetts. They showed that anesthetic drugs did not increase mortality, disputing the findings of previous studies, but they increased hospital length of stay (LOS). By controlling for refractoriness, the authors addressed the major critique of previous studies: that those who needed anesthetic drugs had more refractory SE than those who did not. Patients with substantial comorbidities and increased SE Severity Score were most likely to die and these are the patients who are typically treated with anesthetic drugs, explaining the association identified in prior studies. Without underplaying the adverse effects of anesthetic drugs, patients with poorly controlled SE are also at risk of cardiopulmonary injury and renal failure, and when the systemic effects of anesthesia are anticipated and treated early, it likely evens out.
Perhaps equally important is the remarkable difference in the frequency of anesthetic drug use between the 2 centers, despite "relatively uniform treatment guidelines." The authors explored potential reasons for the greater use of therapeutic coma in Massachusetts, including underdosage of the firstand second-line AEDs, which occurred in 88% of patients compared with 57% of patients in Switzerland. One potential interpretation of these results is that better adherence to treatment guidelines reduces the incidence of refractory SE; however, adequacy of first-and second-line treatments was not a predictor of anesthesia use. An alternative explanation is that the systematic use of continuous EEG, more common in Massachusetts, may have identified more NCSE, leading to more treatment escalation. The fact that NCSE in coma was more frequent in Massachusetts supports this theory.
Several important limitations deserve mention. The study lacked the precision to exclude any effect of anesthetic drug use on mortality; however, it showed that a substantial effect did not exist. In addition, the causes of mortality were not systematically assessed, and withdrawal of care may have confounded the results. Finally, whether anesthetic drugs affected cognitive outcomes was not examined.
The primary clinical implication of this study is that anesthetic drug use in refractory SE does not influence the risk-benefit ratio adversely or favorably. Moving the needle a little against the use of anesthetic drugs is cost, a weak argument if the theory that early seizure control with anesthesia prevents neuronal injury proves to be true. The discrepancy in anesthetic drug use between the centers is understandable given the paucity of evidence on which to base guidelines and resultant lack of specific guidance on when to initiate anesthetic drugs.
A careful examination of functional and cognitive outcomes in patients with refractory SE treated with and without anesthetic drugs will be necessary to assess whether there is justification for the longer hospital LOS and associated cost that results from the use of anesthetic drugs. While anesthetic drugs may not be harming patients on the balance, financial and resource utilization concerns will force us to examine their use in more detail to understand whether they do prevent neuronal loss. A randomized controlled study is needed but will be an arduous task, and we believe that the endpoints need adjusting. In examining whether anesthetics alter mortality or functional outcome, as measured by the modified Rankin Scale, we may simply be indirectly measuring the effect of anesthesia on systemic organs. What is perhaps more apropos is the comparison of prolonged poorly controlled SE and prolonged anesthetic drug use in terms of adversely affecting brain function. A detailed cognitive outcome assessment will be necessary to determine the answer.
This study represents a call to action for all hospitals to examine their adherence to treatment guidelines and to ensure adequate and early dosing of first-and second-line drugs, particularly benzodiazepines. It is possible that with excellent adherence to current guidelines, the need for anesthetic drugs may be reduced, reserving them, as the authors advocate, for only the most refractory cases of SE. Clinicians should remain committed to early control of generalized convulsive SE via continuous infusion of IV anesthetic drugs if necessary, in order to protect the brain against excitotoxic cerebral damage. However, it is reasonable to delay initiation of anesthetic drugs in NCSE for which the risk-benefit analysis is less clear.
